GNQ Insilico, a California‑based Techbio company transforming pre‑clinical and clinical development through AI‑driven digital twins and quantum‑enhanced in silico trials.

GNQ’s Digital Twins Platform builds high‑fidelity virtual patient “digital twins” by integrating genomics, epigenetics, clinical, lifestyle, and real‑world data, then uses deep learning, causal inference, and quantum optimization to simulate efficacy, safety, and responder profiles before large capital is committed to Phase 1/2/3 trials. 

Since launch in September 2025, GNQ has generated USD 20M+ in contracted revenue from pharma, payers, and health systems — demonstrating strong market pull and willingness to pay. Our recurring revenue model aligns with multi-year clinical trial timelines.

We're positioned at the intersection of AI, computational biology, and pharma R&D transformation, targeting the ~$60B+ digital twin and in silico trials market.